Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-05-20 pm EDT 5-day change 1st Jan Change
1.04 USD -3.70% Intraday chart for Lineage Cell Therapeutics, Inc. -4.59% -4.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M MT
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit CI
Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors CI
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting CI
Transcript : Lineage Cell Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q4 Revenue $8.9M, vs. Street Est of $2.8M MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury CI
Lineage Cell Therapeutics Launches $14 Million Registered Direct Offering MT
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury CI
Transcript : Lineage Cell Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Posts Q3 Revenue $1.2M, vs. Street Est of $2.6M MT
Lineage Cell Therapeutics, Inc. Announces to Present Rg6501 Phase 1/2A Results to Be Featured At Eyecelerator At 2023 American Academy of Ophthalmology CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration CI
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501 CI
EARNINGS: R&Q Insurance loss swells, Jade Road still selling assets AN
Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501 CI
Transcript : Lineage Cell Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q2 Revenue $3.2M, vs. Street Est of $2.2M MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Lineage Cell Therapeutics, Cancer Research UK Report 'Encouraging' Results in Lung Cancer Trial MT
Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer CI
Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) added to Russell 2500 Index CI
Chart Lineage Cell Therapeutics, Inc.
More charts
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.04 USD
Average target price
5.2 USD
Spread / Average Target
+400.00%
Consensus
  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. News Lineage Cell Therapeutics, Inc.
  5. Lineage Cell Therapeutics, Cancer Research UK Report 'Encouraging' Results in Lung Cancer Trial
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW